Abstracts tagged "Animal models"

Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1337 • 2017 ACR/ARHP Annual Meeting
ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis
David Zammit¹, Sanjeeva Reddy¹, Roger Smith¹, Nitin Damle² and Sandeep Gupta¹, ¹Asana BioSciences LLC, Lawrenceville, NJ, ²Preclinical R&D, Sun Pharma Advanced Research Co. Ltd, Mumbai, India
Background/Purpose: Spleen tyrosine kinase (SYK) and Janus kinase (JAK) mediate signaling in immune cells and hematopoietic cells important for the initiation and progression of rheumatoid…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
Abstract Number: 1339 • 2017 ACR/ARHP Annual Meeting
Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis
Marta Fernandez Bustmanate¹, Jeffrey Smith², Adam Paul Croft³, Gary S. Firestein⁴, Chris Buckley⁵, Shigeki Miyamoto² and Monica Guma⁶, ¹Medicine, UCSD, San Diego, CA, ²Pharmacology, UCSD, La Jolla, CA, ³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Medicine, University of California San Diego, La Jolla, CA, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Medicine, UCSD, La Jolla, CA
Background/Purpose: Recent studies indicate that fibroblast-like synoviocyte (FLS) glucose metabolism is altered in rheumatoid arthritis (RA). Hexokinases (HKs) catalyze the first step in glucose metabolism.…
Abstract Number: 2574 • 2017 ACR/ARHP Annual Meeting
Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation
Mo Yin Mok¹, Ka Sin Law², Wing Yin Kong¹, Ge Liu¹, Wallace Lau², C Luo², FP Huang³, GC Chan⁴ and Kwok Wah Chan³, ¹Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of…
Abstract Number: 11L • 2016 ACR/ARHP Annual Meeting
BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
Kathleen Gillooly¹, Yifan Zhang¹, Xiaoxia Yang¹, Adriana Zupa-Fernandez¹, Lihong Cheng¹, Joann Strnad¹, Mark Cunningham², Elizabeth Heimrich¹, Xiadi Zhou¹, Jing Chen³, Charu Chaudhry³, Sha Li³, Kim McIntyre¹, Julie Carman⁴, Ryan Moslin⁵, Stephen Wrobleski⁵, David Weinstein⁵ and James Burke¹, ¹Immunosciences Discovery Biology, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³Leads Discovery & Optimization, Bristol-Myers Squibb, Princeton, NJ, ⁴Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ⁵Immunosciences Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ

Background/Purpose: Tyk2 mediates signaling downstream of the receptors for IL-12, IL-23 and Type I interferons, all key drivers of autoimmune disorders such as SLE. BMS-986165,…
Abstract Number: 374 • 2016 ACR/ARHP Annual Meeting
Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia
Yuki Domon¹, Naohisa Arakawa¹, Hiroyasu Murasawa², Hiroyuki Kobayashi², Kensuke Saeki² and Yutaka Kitano¹, ¹Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, ²Nihon Bioresearch Inc., Hashima, Japan
Anxiolytic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia Yuki Domona, Naohisa Arakawaa, Hiroyasu Murasawab, Hiroyuki…
Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting
Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Qi Quan Huang¹, Robert Birkett¹, Elyssa L Roberts² and Richard M. Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²northwestern University, Chicago, IL, ³Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…
Abstract Number: 1851 • 2016 ACR/ARHP Annual Meeting
The Effect of Narrow Band Ultraviolet A1 Light on Bleomycin-Induced Mouse Model of Scleroderma
Diana Karpec^1,2, Romualdas Rudys², Laima Leonaviciene², Zygmunt Mackiewicz², Ruta Bradunaite², Gailute Kirdaite², Rita Rugiene² and Algirdas Venalis^2,3, ¹Clinics of Rheumatology, Traumatology-Orthopedics and Reconstructive Surgery, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ²State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ³Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
Background/Purpose: Ultraviolet A1 (UVA1) phototherapy implications for systemic sclerosis still remain the area of research. The aim of the study was to evaluate narrow band…
Abstract Number: 457 • 2016 ACR/ARHP Annual Meeting
Novel Mechanism Mediated By the IL-23/Th17 Axis Contributing to Auto-Immune Arthritis
René Pfeifle¹, Tobias Rothe¹, Natacha Ipseiz¹, Stephan Culemann¹, Ulrike Harre², Gerhard Krönke³ and Georg Schett⁴, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ³Universitätsklinikum Erlangen, Erlangen, Austria, ⁴Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany
Background/Purpose: Checkpoints and mechanisms regulating the onset of rheumatoid arthritis (RA) remain largely elusive. Apart from B cells and auto-antibodies, Th17 cells were shown to…
Abstract Number: 1126 • 2016 ACR/ARHP Annual Meeting
Interleukin-1 Is Not Involved in Synovial Inflammation and Cartilage Destruction in Collagenase-Induced Osteoarthritis
Stephanie van Dalen¹, Arjen Blom¹, Annet Sloetjes¹, Monique M. Helsen¹, Johannes Roth², Thomas Vogl², Wim B. van den Berg¹, Martijn van den Bosch¹ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Osteoarthritis (OA) is characterized by severe cartilage destruction, with a putative role for synovial macrophages. Up to 50% of the patients also show low…
Abstract Number: 1859 • 2016 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediated Fucosylation of TGF-βR1 Is Critical to TGF-β Signaling in Scleroderma and in Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Pei-Suen Tsou^1,2, Yuxuan Du³, Huadong Cui¹, Ellen Cealey³, Nicholas Lepore⁴, Ray A. Ohara¹, Gautam Edhayan¹, Sarah Arwani¹, Rachel Morgan¹, Dinesh Khanna^1,2, David A. Fox¹ and M. Asif Amin⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan Scleroderma Program, Ann Arbor, MI, ³Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by systemic fibrosis. The dysregulation of transforming growth factor-β (TGF-β) signaling causes proliferation of myofibroblasts…
Abstract Number: 458 • 2016 ACR/ARHP Annual Meeting
The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis
Claire E.J. Waterborg¹, Paqui G. Través², Silke Beermann¹, Marije I. Koenders¹, Greg Lemke² and Fons A.J. van de Loo¹, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an unrestrained inflammatory response in selective, anatomically distinct synovial joints. The innate immune system…
Abstract Number: 1128 • 2016 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Inhibits Cartilage Destruction and Bone Erosion in Collagen-Induced Arthritis Model
Kana Hoshino¹, Masayoshi Ohkuro², Wataru Ikeda¹, Tomoya Nakatani¹, Yoshikazu Kuboi³, Naoto Ishii¹, Toshihiko Yamauchi¹, Nobuyuki Yasuda¹ and Toshio Imai¹, ¹KAN Research Institute Inc., Chuo-ku, Kobe-shi, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki-ku, Kawasaki-shi, Japan, ³Medicine Creation. Neuro Business Group, Eisai Co., Ltd., Tsukuba-shi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease leading to joint destruction. In the previous Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN)…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.